Topic: overactive bladder
The drug failed to clearly outperform a generic used as a control, leaving room to doubt whether vibegron poses a big threat to Astellas’ Myrbetriq.
Axonics Modulation Technologies has pulled in a meaty IPO as it looks to compete with medical technology major Medtronic.
Urovant Sciences picked up the global rights to a gene therapy for overactive bladder patients for whom oral drugs do not work.
Urovant filed to raise $150 million in its IPO, which will push the company's lead asset through the clinic in a pair of indications.
The financing comes as Axonics closes in on the end of a clinical trial that will set it up to market the device in the U.S.
A little later than expected, Roivant group company Urovant has started its confirmatory phase 3 program for overactive bladder drug vibegron.
The takeover will give Laborie control of devices for the treatment of overactive bladder and stress urinary incontinence.
Axonics Modulation Technologies' approach is based on a technique known as sacral neuromodulation, which treats overactive bladder by delivering electrical stimulation to the sacral nerve, helping to correct erroneous messages sent between the bladder and the brain.
The series B round equips Amphora to take its minimally invasive, cystoscopic device into the last step of clinical development next year.
Axonics Modulation Technologies raised $20.5 million in the second closing of its series C financing.